Overview

Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients

Status:
Completed

Trial end date:
2020-07-13

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate if the treatment could maximize intestinal absorption, minimize the inconvenience of diarrhea, and avoid, reduce or eliminate the need for parenteral support (PS) to achieve normal growth, to avoid parenteral nutrition complications and to achieve the best possible quality of life for the patient

Phase:

Phase 4

Details

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Collaborator:

Imagine Institute

Treatments:

Teduglutide